Last reviewed · How we verify
ANXV
ANXV is a small molecule that modulates the activity of certain proteins involved in anxiety disorders.
ANXV is a small molecule that modulates the activity of certain proteins involved in anxiety disorders. Used for Generalized anxiety disorder.
At a glance
| Generic name | ANXV |
|---|---|
| Sponsor | Annexin Pharmaceuticals AB |
| Drug class | anxiolytic |
| Target | GABA_A receptor |
| Modality | Biologic |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
ANXV works by targeting specific proteins in the brain that are involved in the regulation of anxiety. By modulating the activity of these proteins, ANXV aims to reduce anxiety symptoms in patients. Further research is needed to fully understand its mechanism of action.
Approved indications
- Generalized anxiety disorder
Common side effects
- Dizziness
Key clinical trials
- Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion (PHASE2)
- Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (PHASE2)
- First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANXV CI brief — competitive landscape report
- ANXV updates RSS · CI watch RSS
- Annexin Pharmaceuticals AB portfolio CI